Janet L Kwiatkowski, MD, MSCE

faculty photo
Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
Division of Hematology
3401 Civic Center Blvd
Colket Translational Research Building, Room 11024
Philadelphia, PA 19104
Office: 215-590-5286
Education:
B.S. (Zoology)
Duke University, summa cum laude, 1988.
M.D.
Columbia University, College of Physicians & Surgeons, 1992.
MSCE (Clinical Epidemiology and Biostatistics)
University of Pennsylvania, 2003.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Optimization of iron chelation, monitoring transfusional iron overload, stroke prevention in sickle cell disease, headaches in sickle cell disease, complications of thalassemia, transfusion therapy, gene therapy for hemoglobinopathies

Description of Clinical Expertise

General pediatric hematology, iron deficiency anemia, thalassemia, sickle cell disease, transfusional iron overload, chelation therapy

Selected Publications

Bianchi P, Fermo E, Lezon-Geyda K, van Beers EJ, Morton HD, Barcellini W, Glader B, Chonat S, Ravindranath Y, NewbergerPE, Kollmar N, Despotovic JM, Verhovsek M, Sharma M, Kwiatkowski JL, Kuo KHM, Wlodarski MW, Yaish HM, Holzhauer S, Wang H, Kunz J, Addonizio K, Al-Sayegh H, London WB, Andres O, van Wijk R, Gallager PG, Grace RFF: Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. Am J Hematol 95(5): 472-82, May 2020.

Chou ST, Alsawas M, Fasano RM, Field JJ, Hendrickson JE, Howard J, Kameka M, Kwiatkowski JL, Pirenne F, Shi PA, Stowell SR, Thein SL, Westhoff CM, Wong TE, Akl EA: American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 4(2): 327-355, Jan 2020.

Kwiatkowski, JL: Thalassemia syndromes. Nelson Textbook of Pediatrics. Kliegman, St Geme, Blum, Shah, Tasker, Wilson (eds.). Elsevier, Ed 21(2): 2554-2558, 2020.

Kwiatkowski JL, Voeks JH, Kanter J, Fullerton HJ, Debenham E, Brown L, Adams RJ, Post STOP Study Group: Ischemic stroke in children and young adults with sickle cell disease in the Post-STOP era. Am J Hematol 94(12): 1335-1243, December 2019.

Lal A, Locatelli F, Kwiatkowski JL, Kulozik AE, Yannaki E, Porter JB, Thuret I, Sauer MG, Elliot H, Chen Y, Colvin RA, Thompson AA: Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent Beta-Thalassemia and Either a Beta0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene. Blood 134(Suppl 1): 815, Nov 2019.

Al-Samkari H, van Beers EJ, Morton DH, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N, Despotovic JM, Pospisilova D, Knoll CM, kwiatkowski JL, Pastore YD, Thompson AA, Wlodarski MW, Ravindranath Y, Rothman JA, Wang H, Holzhauer S, Breakey VR, Verhovsek MM, Kunz JB, Sheth S, Sharma M, Rose, MJ, Bradeen H, McNaull MA, Addonizio K, Al-Sayegh H, London WB, Grace RF: Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency. Blood 134(Suppl 1), Nov 2019.

Kwiatkowski JL, Elalfy MS, Fradette C, hamdy M, El-Beshlawy A, Ebeid FSE, Verissimo M, Badr MA, Abdulrahman A, Kanter J, inusa BPD, Bejaoui M, Williams S, Kilinc Y, Tsang Y-C, Stilman A, Rozova A, Sinclair J, Shaw D, Chan T, Temin NT, Lee D, Spino M, Tricta F: Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded patients with Sickle Cell Disease and Other Anemias. Blood 134(Suppl 1), Nov 2019 Notes: Oral presentation.

Kanter J, Tisdale JF, Mapara MY, Kwiatkowski JL, Krishnamurti L, Schmidt M, Miller AL, Pierciey FJ, Huang W, Ribeil J-A, Thompson AA, Walters MC: Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: updated Results from the Phase 1/2 Hgb-206 Group C Study. Blood 134(Suppl 1): 990, Nov 2019.

Breda L, Ghiaccio V, Lourenco SP, Jarocha DJ, Ikawa Y, Tanaka N, Guzikowski V, Casu C, Smith-Whitley K, Kwiatkowski JL, Rivella S.: Preclinical Evaluation of ALS20, a New and Improved Lentiviral Vector for Beta-Globinopathies. Blood 134(Suppl 1): 2242, Nov 2019.

Kwiatkowski JL, Thompson AA, Rasko, JEJ, Hongeng S, Schiller, G, Anurathapan U, Cavazzana M, Ho PJ, Schmidt M, Kletzel M, Vichinsky EP, Deary B, Chen Y, Petrusich A, Walters, MC: Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar (HGB-204) Study. Blood 134(Suppl 1): 4628, Nov 2019 Notes: Poster presentation.

back to top
Last updated: 01/07/2021
The Trustees of the University of Pennsylvania